BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) have received an average rating of “Moderate Buy” from the sixteen research firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and eleven have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $140.1029.

A number of analysts have recently issued reports on BNTX shares. UBS Group raised shares of BioNTech to a “hold” rating in a report on Thursday, December 4th. Jefferies Financial Group restated a “buy” rating and set a $151.00 price target on shares of BioNTech in a research report on Wednesday, December 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $140.00 target price on shares of BioNTech in a research note on Thursday, December 11th. Morgan Stanley restated an “overweight” rating and set a $134.00 target price on shares of BioNTech in a report on Monday, November 3rd. Finally, Berenberg Bank reiterated a “buy” rating on shares of BioNTech in a report on Friday, January 23rd.

Institutional Investors Weigh In On BioNTech

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BNTX. Vontobel Holding Ltd. lifted its holdings in shares of BioNTech by 17.9% during the third quarter. Vontobel Holding Ltd. now owns 72,096 shares of the company’s stock valued at $7,110,000 after purchasing an additional 10,924 shares in the last quarter. Allianz SE lifted its stake in BioNTech by 635.0% during the 2nd quarter. Allianz SE now owns 5,880 shares of the company’s stock valued at $626,000 after acquiring an additional 5,080 shares during the period. Dodge & Cox purchased a new stake in shares of BioNTech during the 2nd quarter valued at about $93,421,000. Lingohr Asset Management GmbH grew its stake in shares of BioNTech by 598.4% in the third quarter. Lingohr Asset Management GmbH now owns 47,643 shares of the company’s stock worth $4,699,000 after acquiring an additional 40,821 shares during the period. Finally, LBP AM SA raised its holdings in shares of BioNTech by 15.7% during the third quarter. LBP AM SA now owns 353,329 shares of the company’s stock valued at $34,845,000 after purchasing an additional 47,859 shares during the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Stock Up 2.3%

BNTX stock opened at $110.42 on Friday. The company’s 50 day moving average is $103.88 and its 200 day moving average is $103.56. The stock has a market cap of $24.86 billion, a price-to-earnings ratio of -41.98 and a beta of 1.49. The company has a current ratio of 7.12, a quick ratio of 7.02 and a debt-to-equity ratio of 0.01. BioNTech has a 1-year low of $81.20 and a 1-year high of $124.00.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.